Do you want to read an article? Please log in or register.
Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia
Leukemia
Related content
RECOMMENDED
Leukemia
IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics
★ 2
Recommended by
Prof. Dr Christoph Renner, Faculty Member
Blood.
Nadeu F, Royo R, Clot G, Duran-Ferrer M, Navarro A, Martin S, Lu J, Zenz T, Baumann TS, Jares P, Puente XS, Martin-Subero I, Delgado J, Campo E
doi: 10.1182/blood.2020008311.
RECOMMENDED
Leukemia
Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism
★ 2
Recommended by
Alexander Meisel, Faculty Member
Leukemia.
Hasan MK, Ghia EM, Rassenti LZ, Widhopf GF 2nd, Kipps TJ
doi: 10.1038/s41375-020-01055-7.Visit the original publication at ncbi.nlm.nih.gov
Leukemia
TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
doi: 10.3324/haematol.2018.187583.
Leukemia
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
Drug Des Devel Ther.
Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V
doi: 10.2147/
RECOMMENDED
Leukemia
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1182/blood.2019003453.
LeukemiaLymphoma
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length
Leuk Lymphoma.
Ammann EM, Shanafelt TD, Wright KB, McDowell BD, Link BK, Chrischilles EA
doi: 10.1080/
RECOMMENDED
Leukemia
Remission maintenance treatment options in chronic lymphocytic leukemia
Cancer Treat Rev.
Egle A, Pleyer L, Melchardt T, Hartmann TN, Greil R
doi: 10.1016/j.ctrv.2018.08.003.
Leukemia
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
Leukemia.
Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F
doi: 10.1038/leu.2016.359
EHA® 25 Virtual
Lymphoma
Chronic Lymphocytic Leukemia
Siddiqi et al. 2020. First-line ibrutinib (IBR) + venetoclax (VEN) for patients (PTS) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): efficacy and safety results from CAPTIVATE MRD cohort.
Oral presentation presented at: EHA25 VIRTUAL; 11−21 June 2020.